Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

SBC Medical Group Holdings (SBC) EBIT (2023 - 2025)

SBC Medical Group Holdings (SBC) has disclosed EBIT for 3 consecutive years, with $15.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT rose 14.79% year-over-year to $15.9 million, compared with a TTM value of $59.4 million through Sep 2025, down 49.31%, and an annual FY2024 reading of $70.3 million, down 0.5% over the prior year.
  • EBIT was $15.9 million for Q3 2025 at SBC Medical Group Holdings, up from $14.6 million in the prior quarter.
  • Across five years, EBIT topped out at $51.5 million in Q4 2023 and bottomed at -$473374.0 in Q2 2023.
  • Average EBIT over 3 years is $17.8 million, with a median of $15.9 million recorded in 2025.
  • Peak annual rise in EBIT hit 6397.1% in 2024, while the deepest fall reached 90.84% in 2024.
  • Year by year, EBIT stood at $51.5 million in 2023, then tumbled by 90.84% to $4.7 million in 2024, then skyrocketed by 236.63% to $15.9 million in 2025.
  • Business Quant data shows EBIT for SBC at $15.9 million in Q3 2025, $14.6 million in Q2 2025, and $24.2 million in Q1 2025.